Compare · NVO vs ZTS
NVO vs ZTS
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zoetis Inc. (ZTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZTS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.77B, about 6.1x ZTS ($32.52B).
- Over the past year, NVO is down 39.5% and ZTS is down 54.2% - NVO leads by 14.7 points.
- Both names hit the wire about 11 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 24 for ZTS).
- Company
- Novo Nordisk A/S
- Zoetis Inc.
- Price
- $44.05-3.39%
- $77.60-0.05%
- Market cap
- $196.77B
- $32.52B
- 1M return
- +4.41%
- -32.50%
- 1Y return
- -39.50%
- -54.19%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2013
- News (4w)
- 11
- 11
- Recent ratings
- 25
- 24
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Zoetis Inc.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, blood glucose monitors, and laboratory services; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest ZTS
- SEC Form SD filed by Zoetis Inc.
- Zoetis downgraded by Argus
- Director Stetter Mark converted options into 1,572 shares (SEC Form 4)
- Zoetis Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Parent Louise M converted options into 12,130 shares, increasing direct ownership by 75% to 28,394 units (SEC Form 4)
- Zoetis to Participate in Upcoming Investor Conferences
- Zoetis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Zoetis Declares Third Quarter 2026 Dividend
- Director Damelio Frank A bought $501,344 worth of shares (6,650 units at $75.39), increasing direct ownership by 45% to 21,458 units (SEC Form 4)
- Director Bisaro Paul bought $151,750 worth of shares (2,000 units at $75.88), increasing direct ownership by 8% to 27,862 units (SEC Form 4)